[go: up one dir, main page]

US20100324289A1 - Chemical Process - Google Patents

Chemical Process Download PDF

Info

Publication number
US20100324289A1
US20100324289A1 US12/871,993 US87199310A US2010324289A1 US 20100324289 A1 US20100324289 A1 US 20100324289A1 US 87199310 A US87199310 A US 87199310A US 2010324289 A1 US2010324289 A1 US 2010324289A1
Authority
US
United States
Prior art keywords
compound
formula
hydrogenation
catalyst
platinum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/871,993
Inventor
Ulf Larsson
Kajsa Rådevik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to US12/871,993 priority Critical patent/US20100324289A1/en
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LARSSON, ULF, RADEVIK, KAJSA
Publication of US20100324289A1 publication Critical patent/US20100324289A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • the present invention concerns a process fox the preparation of 5-aminopyrimidines which are useful intermediates in the preparation of pharmaceutically active triazolo[4,5-d]pyrimidine cyclopentanes.
  • the present invention provides a process for the preparation of a compound of formula (I):
  • X is halogen
  • Y is ZR 1
  • Z is oxygen or sulphur
  • R 1 is C 1-6 alkyl, C 1-6 haloalkyl or C 3-7 cycloalkyl; the process comprising either:
  • Alkyl groups and moieties are straight or branched chain and comprise, for example, 1 to 6 (such as 1 to 4) carbon atoms.
  • alkyl groups are methyl, ethyl, n-propyl, iso-propyl or tert-butyl.
  • Haloalkyl groups and moieties are straight or branched chain and comprise, for example, 1 to 6 (such as 1 to 4) carbon atoms, and 1 to 6 halogen atoms (for example fluorine or chlorine atoms).
  • haloalkyl are CH 2 F, CHF 2 , CF 3 , CH 2 CF 3 and 3,3,3-trifluoroprop-1-yl.
  • Cycloalkyl is, for example, C 3-6 cycloalkyl, such as cyclopropyl, cyclopentyl or cyclohexyl.
  • the present invention provides a process for the preparation of a compound of formula (I):
  • Suitable transition metal catalyst for the hydrogenation of a compound of formula (II) is, for example, platinum or palladium, or a combination of platinum with another transition metal such as vanadium, iron or manganese.
  • the transition metal catalyst is on a suitable support, for example carbon.
  • a suitable solvent for the hydrogenation of a compound of formula (II) is a C 1-6 aliphatic alcohol (such as ethanol and iso-propyl alcohol), an ether (for example a di(C 1-6 alkyl) ether, such as diethylether or methyl tert-butyl ether; or a cyclic ether such as tetrahydrofuran), an ester (for example ethyl acetate) or a hydrocarbon solvent (such as an aromatic hydrocarbon, for example benzene, toluene or a xylene).
  • a C 1-6 aliphatic alcohol such as ethanol and iso-propyl alcohol
  • an ether for example a di(C 1-6 alkyl) ether, such as diethylether or methyl tert-butyl ether; or a cyclic ether such as tetrahydrofuran
  • an ester for example ethyl acetate
  • the hydrogenation of a compound of formula (II) is conducted at a temperature in the range 10 to 90° C., for example 20 to 40° C.
  • the hydrogenation of a compound of formula (II) is conducted at a pressure of 1 to 10 bar, for example 2 to 4 bar.
  • the present invention provides a process for the preparation of a compound of formula (I):
  • R 2 is phenyl optionally substituted by chloro, C 1-6 alkyl, C 1-6 alkoxy or (C 1-6 alkyl) 2 N;
  • Highly effective mixing for example stirring is used during the one-pot hydrogenation as this aids effective mass transfer during the process.
  • Highly effective mixing is used to obtain good contact between the gaseous hydrogen, the solid catalyst and the compound of formula (III) or (IV).
  • a suitable catalyst for the one-pot hydrogenation is either a single transition metal or a mixture of two or more transition metals.
  • Suitable catalysts are platinum or a mixture of platinum and vanadium. It is usual for the catalyst to be on a suitable support (for example carbon). Examples of these catalysts are platinum on carbon 5-15% w/w; platinum 2-10% w/w (for example 3-7% w/w) and vanadium 0.2-3% w/w on carbon.
  • a suitable solvent for the one-pot hydrogenation is a C 1-6 aliphatic alcohol (for example ethanol or iso-propyl alcohol), an ester (for example ethyl acetate), an ether (such as tetrahydrofuran or methyl tert-butyl ether), a hydrocarbon (such as an aromatic hydrocarbon, for example benzene, toluene or a xylene) or a ketone (such as acetone).
  • a C 1-6 aliphatic alcohol for example ethanol or iso-propyl alcohol
  • an ester for example ethyl acetate
  • an ether such as tetrahydrofuran or methyl tert-butyl ether
  • a hydrocarbon such as an aromatic hydrocarbon, for example benzene, toluene or a xylene
  • ketone such as acetone
  • the hydrogenation of a compound of formula (III) or (IV) is conducted at a pressure of 0.5 to 10 bar, for example 2 to 4 bar.
  • the present invention provides a process as hereinbefore described wherein X is chloro.
  • the present invention provides a process as hereinbefore described wherein Z is sulphur.
  • the present invention provides a process as hereinbefore described wherein R 1 is C 1-4 alkyl (such as n-propyl) or C 1-4 haloalkyl (such as 3,3,3-trifluoroprop-1-yl).
  • the present invention provides a process as herein described where in 5-15% w/w catalyst is used based on compound of formula (II) or (III).
  • This Example illustrates a process for the preparation of 4,6-dichloro-2-(propylthio)pyrimidin-5-amine.
  • a Pt/V/C catalyst (available from Degussa; about 3% Pt and 0.6% V adsorbed on charcoal, 30 g) was charged to a vessel and the vessel was purged with nitrogen.
  • 4,6-Dichloro-5-nitro-2-(propylthio)pyrimidine (302 g) dissolved in tert-butyl methyl ether (31) was charged to the vessel and agitation was started. The resulting mixture was heated to an initial temperature of 30° C. and then the vessel was pressurised with hydrogen to 3 bar for 3 hours. After the completion of the hydrogenation the catalyst was filtered off. The filtrate was concentrated under reduced pressure to provide the title compound (254 g).
  • This Example illustrates a process for the preparation of 4,6-dichloro-2-(propylthio)pyrimidin-5-amine from 4,6-dichloro-5-[(E)-(4-methylphenyl)diazenyl]-2-(propylsulfanyl)pyrimidine
  • the Pt/C catalyst (33.3 g, 10% w/w) was added to a reaction vessel that had been purged with nitrogen and maintained under an atmosphere of nitrogen.
  • the solution of 4,6-dichloro-5-[(E)-2-(4-methylphenyl)diazenyl]-2-(propylsulfanyl)pyrimidine (150 g, 430.1 mmol) in ethyl acetate (3000 ml ) was added to the reaction vessel containing the catalyst and agitation was initiated.
  • the inner temperature was adjusted to 20° C., the nitrogen atmosphere was evacuated, and the vessel was pressurized with 3 bar of hydrogen (hydrogen pressure of 3 bar was maintained throughout the reaction). The temperature was maintained at 20° C.
  • reaction solution was cooled to 20° C. and the catalyst filtered off under a nitrogen atmosphere.
  • the catalyst was washed with ethyl acetate (300 ml ) and the filtered wash-solution was combined with the filtered reaction solution.
  • the ethyl acetate solution was concentrated to 5m1 (ethyl acetate)/g (amine) under vacuum at a maximum temperature of 40° C.
  • the resulting solution was extracted twice with aqueous hydrochloric acid (about 3M; 700 ml and 375 ml ) until a pH of 1.5-2 was obtained.
  • concentration of the ethyl acetate layer, under vacuum yielded about 93 g of the 4,6-dichloro-2-(propylthio)pyrimidin-5-amine as a yellow oil.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention provides a process for the preparation of a compound of formula (I); wherein X is halogen; Y is ZR1; Z is oxygen or sulphur; and R1 is C1-6 alkyl, C1-6 haloalkyl or C3-7 cloalkyl; the process comprising either: hydrogenating a compound of formula (II); with a suitable transition metal catalyst in a C1-6 aliphatic alcohol, an ether, an hydrocarbon as solvent; or, conducting a one-pot hydrogenation of a compound of formula (III): wherein R2 is phenyl optionally substituted by chloro, C1-6 alkyl, C1-6 alkoxy or (C1-6 alkyl)2N; firstly at about 20° C. to form a compound of formula (IV): and then at about 40° C.; both steps (I) and (ii) being carried out in the presence of a suitable catalyst and in the presence of a suitable solvent.
Figure US20100324289A1-20101223-C00001

Description

  • The present invention concerns a process fox the preparation of 5-aminopyrimidines which are useful intermediates in the preparation of pharmaceutically active triazolo[4,5-d]pyrimidine cyclopentanes.
  • The compound [1S-(1α, 2α, 3β (1S*,2R*),5β)]-3-[7-[2-(3,4-difluorophenyl)-cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)-cyclopentane-1,2-diol (Compound A), and similar such compounds, are disclosed in WO 00/34283 and WO 99/05143 as pharmaceutically active P2T (which is now usually referred to as P2Y12) receptor antagonists. Such antagonists can be used as, inter alia, inhibitors of platelet activation, aggregation or degranulation.
  • Compounds of formula (I) (see below) are useful in the preparation of Compound A and analogues thereof (see example 3 of WO 01/92263).
  • Catalytic hydrogenation of aromatic nitro compounds is disclosed in U.S. Pat. No. 6,09,6924.
  • The present invention provides a process for the preparation of a compound of formula (I):
  • Figure US20100324289A1-20101223-C00002
  • wherein X is halogen; Y is ZR1; Z is oxygen or sulphur; and R1 is C1-6 alkyl, C1-6 haloalkyl or C3-7 cycloalkyl; the process comprising either:
    • a. hydrogenating a compound of formula (II):
  • Figure US20100324289A1-20101223-C00003
    •  with a suitable transition metal catalyst in a C1-6 aliphatic alcohol, an ether, an ester or a hydrocarbon as solvent;
    •  or,
    • b. conducting a one-pot hydrogenation of a compound of formula (III):
  • Figure US20100324289A1-20101223-C00004
    •  wherein R2 is phenyl optionally substituted by chloro, C1-6 alkyl, C1-6 alkoxy or (C1-6 alkyl)2N;
      • i. firstly at about 20° C. to form a compound of formula (IV):
  • Figure US20100324289A1-20101223-C00005
      • ii. and then at about 40° C.;
    • both steps (i) and (ii) being carried out in the presence of a suitable catalyst and in the presence of a suitable solvent.
  • Alkyl groups and moieties are straight or branched chain and comprise, for example, 1 to 6 (such as 1 to 4) carbon atoms. Examples of alkyl groups are methyl, ethyl, n-propyl, iso-propyl or tert-butyl.
  • Haloalkyl groups and moieties are straight or branched chain and comprise, for example, 1 to 6 (such as 1 to 4) carbon atoms, and 1 to 6 halogen atoms (for example fluorine or chlorine atoms). Examples of haloalkyl are CH2F, CHF2, CF3, CH2CF3 and 3,3,3-trifluoroprop-1-yl.
  • Cycloalkyl is, for example, C3-6 cycloalkyl, such as cyclopropyl, cyclopentyl or cyclohexyl.
  • In one particular aspect the present invention provides a process for the preparation of a compound of formula (I):
  • Figure US20100324289A1-20101223-C00006
  • wherein X is halogen; Y is ZR1; Z is oxygen or sulphur; and R1 is C1-6 alkyl, C1-6 haloalkyl or C3-7 cycloalkyl; the process comprising hydrogenating a compound of formula (II):
  • Figure US20100324289A1-20101223-C00007
  • with a suitable transition metal catalyst in C1-6 aliphatic alcohol, an ether, an ester or a hydrocarbon as solvent.
  • Suitable transition metal catalyst for the hydrogenation of a compound of formula (II) is, for example, platinum or palladium, or a combination of platinum with another transition metal such as vanadium, iron or manganese. In a further aspect of the invention the transition metal catalyst is on a suitable support, for example carbon.
  • A suitable solvent for the hydrogenation of a compound of formula (II) is a C1-6 aliphatic alcohol (such as ethanol and iso-propyl alcohol), an ether (for example a di(C1-6 alkyl) ether, such as diethylether or methyl tert-butyl ether; or a cyclic ether such as tetrahydrofuran), an ester (for example ethyl acetate) or a hydrocarbon solvent (such as an aromatic hydrocarbon, for example benzene, toluene or a xylene).
  • In another aspect the hydrogenation of a compound of formula (II) is conducted at a temperature in the range 10 to 90° C., for example 20 to 40° C.
  • In yet another aspect the hydrogenation of a compound of formula (II) is conducted at a pressure of 1 to 10 bar, for example 2 to 4 bar.
  • In a further aspect the present invention provides a process for the preparation of a compound of formula (I):
  • Figure US20100324289A1-20101223-C00008
  • wherein X is halogen; Y is ZR1; Z is oxygen or sulphur; and R1 is C1-6 alkyl, C1-6 haloalkyl or C3-7 cycloalkyl; the process comprising conducting a one-pot hydrogenation of a compound of formula (III):
  • Figure US20100324289A1-20101223-C00009
  • wherein R2 is phenyl optionally substituted by chloro, C1-6 alkyl, C1-6 alkoxy or (C1-6 alkyl)2N;
    • i. firstly at 10 to 25° C. to form a compound of formula (IV):
  • Figure US20100324289A1-20101223-C00010
    • ii. and then hydrogenating at about 35 to 50° C.;
    •  both steps (i) and (ii) being carried out in the presence of a suitable catalyst and in the presence of a suitable solvent.
  • Highly effective mixing (for example stirring) is used during the one-pot hydrogenation as this aids effective mass transfer during the process. Highly effective mixing is used to obtain good contact between the gaseous hydrogen, the solid catalyst and the compound of formula (III) or (IV).
  • A suitable catalyst for the one-pot hydrogenation is either a single transition metal or a mixture of two or more transition metals. Suitable catalysts are platinum or a mixture of platinum and vanadium. It is usual for the catalyst to be on a suitable support (for example carbon). Examples of these catalysts are platinum on carbon 5-15% w/w; platinum 2-10% w/w (for example 3-7% w/w) and vanadium 0.2-3% w/w on carbon.
  • A suitable solvent for the one-pot hydrogenation is a C1-6 aliphatic alcohol (for example ethanol or iso-propyl alcohol), an ester (for example ethyl acetate), an ether (such as tetrahydrofuran or methyl tert-butyl ether), a hydrocarbon (such as an aromatic hydrocarbon, for example benzene, toluene or a xylene) or a ketone (such as acetone).
  • In yet another aspect the hydrogenation of a compound of formula (III) or (IV) is conducted at a pressure of 0.5 to 10 bar, for example 2 to 4 bar.
  • In a still further aspect the present invention provides a process as hereinbefore described wherein X is chloro.
  • In another aspect the present invention provides a process as hereinbefore described wherein Z is sulphur.
  • In yet another aspect the present invention provides a process as hereinbefore described wherein R1 is C1-4 alkyl (such as n-propyl) or C1-4 haloalkyl (such as 3,3,3-trifluoroprop-1-yl).
  • In yet another aspect the present invention provides a process as herein described where in 5-15% w/w catalyst is used based on compound of formula (II) or (III).
  • The following Examples illustrate the invention.
  • EXAMPLE 1
  • This Example illustrates a process for the preparation of 4,6-dichloro-2-(propylthio)pyrimidin-5-amine.
  • A Pt/V/C catalyst (available from Degussa; about 3% Pt and 0.6% V adsorbed on charcoal, 30 g) was charged to a vessel and the vessel was purged with nitrogen. 4,6-Dichloro-5-nitro-2-(propylthio)pyrimidine (302 g) dissolved in tert-butyl methyl ether (31) was charged to the vessel and agitation was started. The resulting mixture was heated to an initial temperature of 30° C. and then the vessel was pressurised with hydrogen to 3 bar for 3 hours. After the completion of the hydrogenation the catalyst was filtered off. The filtrate was concentrated under reduced pressure to provide the title compound (254 g).
  • EXAMPLE 2
  • This Example illustrates a process for the preparation of 4,6-dichloro-2-(propylthio)pyrimidin-5-amine from 4,6-dichloro-5-[(E)-(4-methylphenyl)diazenyl]-2-(propylsulfanyl)pyrimidine
  • Figure US20100324289A1-20101223-C00011
  • The Pt/C catalyst (33.3 g, 10% w/w) was added to a reaction vessel that had been purged with nitrogen and maintained under an atmosphere of nitrogen. The solution of 4,6-dichloro-5-[(E)-2-(4-methylphenyl)diazenyl]-2-(propylsulfanyl)pyrimidine (150 g, 430.1 mmol) in ethyl acetate (3000 ml ) was added to the reaction vessel containing the catalyst and agitation was initiated. The inner temperature was adjusted to 20° C., the nitrogen atmosphere was evacuated, and the vessel was pressurized with 3 bar of hydrogen (hydrogen pressure of 3 bar was maintained throughout the reaction). The temperature was maintained at 20° C. for about 30 minutes and then it was increased to 40° C. and maintained for 150 minutes. When the reaction was complete (full conversion) the reaction solution was cooled to 20° C. and the catalyst filtered off under a nitrogen atmosphere. The catalyst was washed with ethyl acetate (300 ml ) and the filtered wash-solution was combined with the filtered reaction solution. The ethyl acetate solution was concentrated to 5m1 (ethyl acetate)/g (amine) under vacuum at a maximum temperature of 40° C. The resulting solution was extracted twice with aqueous hydrochloric acid (about 3M; 700 ml and 375 ml ) until a pH of 1.5-2 was obtained. The concentration of the ethyl acetate layer, under vacuum, yielded about 93 g of the 4,6-dichloro-2-(propylthio)pyrimidin-5-amine as a yellow oil.

Claims (20)

1. A process for the preparation of a compound of formula (I):
Figure US20100324289A1-20101223-C00012
wherein
X is halogen;
Y is ZR1;
Z is oxygen or sulphur; and
R1 is C1-6 alkyl, C1-6 haloalkyl or C3-7 cycloalkyl;
the process comprising either:
hydrogenating a compound of formula (II):
Figure US20100324289A1-20101223-C00013
 with a suitable transition metal catalyst in a C1-6 aliphatic alcohol, an ether, an ester or a hydrocarbon as solvent; or,
conducting a one-pot hydrogenation of a compound of formula (III):
Figure US20100324289A1-20101223-C00014
 wherein R2 is phenyl optionally substituted by chloro, C1-6 alkyl, C1-6 alkoxy or (C1-6 alkyl)2N;
(i) firstly at about 20° C. to form a compound of formula (IV):
Figure US20100324289A1-20101223-C00015
(ii) and then at about 40° C.;
 both steps (i) and (ii) being carried out in the presence of a suitable catalyst and in the presence of a suitable solvent.
2. A process as claimed in claim 1 wherein X is chloro.
3. A process as claimed in claim 1 wherein Z is sulphur.
4. A process as claimed in claim 1, wherein R1 is C1-4 alkyl or C1-4 haloalkyl.
5. A process as claimed in claim 1, wherein Y is ZR1; Z is sulphur; and R1 is n-propyl.
6. A process as claimed in claim 1 wherein the transition metal catalyst for the hydrogenation of a compound of formula (II) is selected from platinum, palladium and a combination of platinum with a transition metal selected from vanadium, iron and manganese.
7. A process as claimed claim 6 wherein the transition metal catalyst is on a carbon support.
8. A process as claimed in claim 1 wherein the solvent for the hydrogenation of a compound of formula (II) is a C1-6 aliphatic alcohol, an ether, an ester or a hydrocarbon solvent.
9. A process as claimed in claim 1 wherein the hydrogenation of a compound of formula (II) is conducted at a temperature in the range 10 to 90° C.
10. A process as claimed in claim 9 wherein the hydrogenation of a compound of formula (II) is conducted at a temperature in the range 20 to 40° C.
11. A process as claimed in claim 1 wherein the hydrogenation of a compound of formula (II) is conducted at a pressure of 1 to 10 bar.
12. A process as claimed in claim 10 wherein the hydrogenation of a compound of formula (II) is conducted at a pressure of 2 to 4 bar.
13. A process as claimed in claim 1 for the preparation of a compound of formula (I) in which X is chloro, Y is ZR1; Z is sulphur; and R1 is n-propyl; the process comprising hydrogenating a compound of formula (II) in solvent comprising an ether at a pressure of 2 to 4 bar, a temperature in the range 20 to 40° C. and a Pt/V/C catalyst.
14. A process as claimed in claim 1 wherein the catalyst for the one-pot hydrogenation is selected from platinum and a mixture of platinum and vanadium.
15. A process as claimed in claim 13 wherein the catalyst for the one-pot hydrogenation is selected from platinum on carbon 5-15% w/w; platinum 2-10% w/w and vanadium 0.2-3% w/w on carbon.
16. A process as claimed in claim 12, wherein the solvent for the one-pot hydrogenation is selected from a C1-6 aliphatic alcohol, an ester, an ether, a hydrocarbon and a ketone.
17. A process as claimed in claim 13, wherein the hydrogenation of a compound of formula (III) or (IV) is conducted at a pressure of 2 to 4 bar.
18. A process as claimed in claim 1 for the preparation of a compound of formula (I) in which X is chloro, Y is ZR1; Z is sulphur; and R1 is n-propyl; the process comprising a one-pot hydrogenation of a compound of formula (III) wherein the hydrogenation is conducted in a solvent of ethyl acetate at a pressure of 2 to 4 bar and using a Pt/C catalyst.
19. A process as claimed in claim 1 wherein:
X is chloro;
Z is sulphur;
R1 is n-propyl;
the transition metal catalyst for the hydrogenation of a compound of formula (II) is selected from platinum, palladium and a combination of platinum with a transition metal selected from vanadium, iron and manganese; and
the solvent for the hydrogenation of a compound of formula (II) is a C1-6 aliphatic alcohol, an ether, an ester or a hydrocarbon solvent;
20. A process as claimed in claim 19 wherein:
the hydrogenation of the compound of formula (II) is conducted at a temperature in the range 20 to 40° C.;
the hydrogenation of the compound of formula (II) is conducted at a pressure of 2 to 4 bar;
the catalyst for the one-pot hydrogenation is selected from platinum on carbon 5-15% w/w, platinum 2-10% w/w and vanadium 0.2-3% w/w on carbon; and
the hydrogenation of the compound of formula (III) or (IV) is conducted at a pressure of 2 to 4 bar.
US12/871,993 2004-03-31 2010-08-31 Chemical Process Abandoned US20100324289A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/871,993 US20100324289A1 (en) 2004-03-31 2010-08-31 Chemical Process

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0401001A SE0401001D0 (en) 2004-03-31 2004-03-31 Chemical process
SE0401001-3 2004-03-31
PCT/GB2005/001188 WO2005095358A2 (en) 2004-03-31 2005-03-29 Process for the preparation of aminopyrimidines
US10/599,377 US7799914B2 (en) 2004-03-31 2005-03-29 Chemical process
US12/871,993 US20100324289A1 (en) 2004-03-31 2010-08-31 Chemical Process

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2005/001188 Continuation WO2005095358A2 (en) 2004-03-31 2005-03-29 Process for the preparation of aminopyrimidines
US11/599,377 Continuation US7243186B2 (en) 2003-12-22 2006-11-15 Method of optimizing performance of flash memory

Publications (1)

Publication Number Publication Date
US20100324289A1 true US20100324289A1 (en) 2010-12-23

Family

ID=32294337

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/599,377 Expired - Fee Related US7799914B2 (en) 2004-03-31 2005-03-29 Chemical process
US12/871,993 Abandoned US20100324289A1 (en) 2004-03-31 2010-08-31 Chemical Process

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/599,377 Expired - Fee Related US7799914B2 (en) 2004-03-31 2005-03-29 Chemical process

Country Status (23)

Country Link
US (2) US7799914B2 (en)
EP (2) EP1751117B1 (en)
JP (1) JP5059599B2 (en)
KR (1) KR101164265B1 (en)
CN (2) CN101851212A (en)
AT (1) ATE517096T1 (en)
AU (1) AU2005227727B2 (en)
BR (1) BRPI0509323A (en)
CA (1) CA2560094C (en)
CY (1) CY1111847T1 (en)
DK (1) DK1751117T3 (en)
ES (1) ES2368069T3 (en)
HR (1) HRP20110658T1 (en)
IL (1) IL177998A (en)
NO (1) NO20064117L (en)
NZ (2) NZ550128A (en)
PL (1) PL1751117T3 (en)
PT (1) PT1751117E (en)
SE (1) SE0401001D0 (en)
SG (1) SG151311A1 (en)
SI (1) SI1751117T1 (en)
WO (1) WO2005095358A2 (en)
ZA (1) ZA200607708B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401001D0 (en) * 2004-03-31 2004-03-31 Astrazeneca Ab Chemical process
CA2636619A1 (en) * 2006-02-13 2007-08-23 Lonza Ag Reduction of 5-(aryl-diazenyl)-4,6-dihalo-pyrimidine
ES2558843T3 (en) 2008-09-09 2016-02-09 Astrazeneca Ab Procedure for preparing [1S- [1-alpha, 2-alpha, 3-beta (1S *, 2R *), 5-beta]] - 3- [7- [2- (3,4-difluorophenyl) -cyclopropylamino] -5- (propylthio) -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -5- (2-hydroxyethoxy) cyclopentane-1,2-diol and its intermediates
EP2305376A1 (en) * 2009-09-23 2011-04-06 Lonza Ltd. Process and catalyst for the catalytic hydrogenation of aromatic and heteroaromatic nitro compounds
EP2834247A4 (en) 2012-04-05 2016-03-30 Reddys Lab Ltd Dr Preparation of ticagrelor
CN103130726A (en) * 2013-02-07 2013-06-05 许学农 Preparation method of Ticagrelor intermediate 4,6-dichloro-2-(pyridinecarboxylic)-5- aminopyrimidine
WO2014206187A1 (en) 2013-06-24 2014-12-31 苏州明锐医药科技有限公司 Preparation method of ticagrelor and intermediates thereof
US10329288B2 (en) 2013-08-22 2019-06-25 Genentech, Inc. Process for preparing a compound
CN103588712B (en) * 2013-11-08 2016-06-08 南京欧信医药技术有限公司 A kind of pyrimidines and preparation method thereof and application
CN103923020A (en) * 2014-04-02 2014-07-16 黄河三角洲京博化工研究院有限公司 Preparation method of 2-propylthio-4,6-dichloro-5-aminopyrimidine
CN105020602B (en) * 2014-04-30 2017-12-08 欧普照明股份有限公司 A kind of LED
CN103992277A (en) * 2014-05-16 2014-08-20 苏州天马精细化学品股份有限公司 Method for preparing intermediate 4,6-dichloro-5-amino-2-propylthiouracil of ticagrelor
CN105294573B (en) * 2015-06-16 2018-07-10 厦门医学院 A kind of method for synthesizing 4,6- bis- chloro- 2- (rosickyite base) -5- aminopyrimidines
CN116283796A (en) * 2023-02-14 2023-06-23 上海汇伦医药股份有限公司 A kind of method of circular catalytic hydrogenation nitro compound

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096924A (en) * 1995-05-19 2000-08-01 Novartis Ag Process for the catalytic hydrogeneration of aromatic nitro compounds
US6818720B2 (en) * 2001-11-08 2004-11-16 Degussa Ag Supported hydrogenating catalyst in powder form
US7067663B2 (en) * 2000-06-02 2006-06-27 Astrazeneca Ab Triazolo pyrimidine compounds
US7799914B2 (en) * 2004-03-31 2010-09-21 Astrazeneca Ab Chemical process

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT64967A (en) * 1991-04-06 1994-03-28 Fisons Plc Atp analogues and pharmaceutical compositions containing them
TW530058B (en) 1997-07-22 2003-05-01 Astra Pharma Prod Triazolo [4,5-d]pyrimidine compounos and their use and process for preparation
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096924A (en) * 1995-05-19 2000-08-01 Novartis Ag Process for the catalytic hydrogeneration of aromatic nitro compounds
US7067663B2 (en) * 2000-06-02 2006-06-27 Astrazeneca Ab Triazolo pyrimidine compounds
US6818720B2 (en) * 2001-11-08 2004-11-16 Degussa Ag Supported hydrogenating catalyst in powder form
US7799914B2 (en) * 2004-03-31 2010-09-21 Astrazeneca Ab Chemical process

Also Published As

Publication number Publication date
AU2005227727B2 (en) 2009-03-26
IL177998A0 (en) 2006-12-31
ZA200607708B (en) 2008-06-25
CN101851212A (en) 2010-10-06
WO2005095358A2 (en) 2005-10-13
DK1751117T3 (en) 2011-10-10
WO2005095358A3 (en) 2006-01-05
JP2007530650A (en) 2007-11-01
CY1111847T1 (en) 2015-10-07
SE0401001D0 (en) 2004-03-31
NZ587999A (en) 2012-04-27
CN1938284B (en) 2010-08-11
PL1751117T3 (en) 2011-11-30
KR101164265B1 (en) 2012-07-09
JP5059599B2 (en) 2012-10-24
ATE517096T1 (en) 2011-08-15
EP1751117A2 (en) 2007-02-14
CA2560094A1 (en) 2005-10-13
CN1938284A (en) 2007-03-28
NO20064117L (en) 2006-10-30
US7799914B2 (en) 2010-09-21
HRP20110658T1 (en) 2011-10-31
US20070219371A1 (en) 2007-09-20
BRPI0509323A (en) 2007-09-04
HK1103727A1 (en) 2007-12-28
IL177998A (en) 2012-03-29
NZ550128A (en) 2010-10-29
EP1751117B1 (en) 2011-07-20
CA2560094C (en) 2012-10-30
SI1751117T1 (en) 2011-10-28
EP2308853A1 (en) 2011-04-13
KR20060133019A (en) 2006-12-22
SG151311A1 (en) 2009-04-30
AU2005227727A1 (en) 2005-10-13
PT1751117E (en) 2011-09-19
ES2368069T3 (en) 2011-11-14

Similar Documents

Publication Publication Date Title
US20100324289A1 (en) Chemical Process
US7759486B2 (en) 2,4,5-Trisubstituted pyrimidine compounds
PL198640B1 (en) PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
US20050288503A1 (en) Novel compounds
US12187714B2 (en) Process for preparing aminopyrimidine derivatives
US8242044B2 (en) Process and catalyst
HK1156029A (en) Process for the preparation of aminopyrimidines
CZ20031021A3 (en) Process for preparing substituted aniline derivatives
HK1103727B (en) Process for the preparation of aminopyrimidines
MXPA06011235A (en) Chemical process
JP5078607B2 (en) Chemical process
HK1172580B (en) A process and catalyst for the catalytic hydrogenation of aromatic and heteroaromatic nitro compounds
MXPA06011231A (en) Chemical process

Legal Events

Date Code Title Description
AS Assignment

Owner name: ASTRAZENECA AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LARSSON, ULF;RADEVIK, KAJSA;REEL/FRAME:024948/0620

Effective date: 20060825

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION